Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex to Present at Sigma-1 Receptors SymposiumNextNext post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)July 17, 2019Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) MeetingOctober 26, 2018Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2018
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)July 17, 2019
Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) MeetingOctober 26, 2018
Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2018
